GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taiko Pharmaceutical Co Ltd (TSE:4574) » Definitions » Gross Profit

Taiko Pharmaceutical Co (TSE:4574) Gross Profit : 円2,802 Mil (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Taiko Pharmaceutical Co Gross Profit?

Taiko Pharmaceutical Co's gross profit for the three months ended in Mar. 2024 was 円799 Mil. Taiko Pharmaceutical Co's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was 円2,802 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Taiko Pharmaceutical Co's gross profit for the three months ended in Mar. 2024 was 円799 Mil. Taiko Pharmaceutical Co's Revenue for the three months ended in Mar. 2024 was 円1,377 Mil. Therefore, Taiko Pharmaceutical Co's Gross Margin % for the quarter that ended in Mar. 2024 was 58.02%.

Taiko Pharmaceutical Co had a gross margin of 58.02% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Taiko Pharmaceutical Co was 74.51%. The lowest was 21.39%. And the median was 69.10%.

Warning Sign:

Taiko Pharmaceutical Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -22%.


Taiko Pharmaceutical Co Gross Profit Historical Data

The historical data trend for Taiko Pharmaceutical Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiko Pharmaceutical Co Gross Profit Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,552.47 7,161.83 10,578.37 2,746.00 1,078.00

Taiko Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 574.00 476.00 741.00 786.00 799.00

Competitive Comparison of Taiko Pharmaceutical Co's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Taiko Pharmaceutical Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiko Pharmaceutical Co's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taiko Pharmaceutical Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Taiko Pharmaceutical Co's Gross Profit falls into.



Taiko Pharmaceutical Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Taiko Pharmaceutical Co's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=5040 - 3962
=1,078

Taiko Pharmaceutical Co's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=1377 - 578
=799

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円2,802 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Taiko Pharmaceutical Co's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=799 / 1377
=58.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Taiko Pharmaceutical Co  (TSE:4574) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Taiko Pharmaceutical Co had a gross margin of 58.02% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Taiko Pharmaceutical Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiko Pharmaceutical Co (TSE:4574) Business Description

Traded in Other Exchanges
N/A
Address
No. 34 Third Street, No. 14, Uchihon Suita, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.

Taiko Pharmaceutical Co (TSE:4574) Headlines

No Headlines